Amgen Stock Analysis by Value InvestorRead More »
This content is restricted to site members. If you are an existing user, please log in. New users may register below.
Amgen Stock Analysis by Value Investor
Views: 112 2026-07-23 Amgen is a large biotechnology company headquartered in Thousand Oaks, California, founded over 40 years ago. It discovers, develops, manufactures, and sells biologic therapeutics for oncology, cardiovascular disease, osteoporosis, inflammation, and rare diseases. Core franchises include Prolia, Repatha, Otezla, Enbrel, Xgeva, Tezspire, and a growing biosimilars business. Amgen made a transformational $27.8 billion acquisition of Horizon Therapeutics in 2023, adding rare-disease drugs like Tepezza and Uplizna but substantially increasing debt. The company is now investing heavily in MariTide, an experimental monthly obesity injection in Phase 3 trials, positioned as a potential differentiator against Eli Lilly and Novo …
